cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.25934/00001522
title: An Open Label Positron Emission Tomography (PET) Imaging Study Using 89Zirconium to Investigate the Biodistribution of Anti-HER3 Monoclonal Antibody (mAb) GSK2849330 and Characterize Its Dose-receptor Occupancy Relationship in Subjects With Advanced HER3-Positive Solid Tumors

description: Human epidermal growth factor receptor 3 (HER3) expression is seen across a wide variety of solid malignancies and is associated with poor prognosis. Up-regulation of HER3 expression and activity is also associated with resistance to multiple pathway inhibitors. GSK2849330, a monoclonal antibody (mAb) targeting HER3, is a new agent for subjects whose tumors express HER3. This study aims to characterise the biodistribution and dose-receptor occupancy relationship of GSK2849330 in patients with advanced HER3 expressing solid tumours via the use of PET imaging. This study will be conducted in two parts. Part 1 will be the imaging phase where each subject will receive two doses of GSK2849330 containing both Zirconium-89 (89Zr) labelled GSK2849330 and unlabeled GSK2849330. The amount of unlabeled GSK2849330 present in each dose will be varied to explore the effect on target mediated uptake of 89Zr into HER3 expressing tissues and tumors. Subjects will then proceed to the continuation phase (Part 2) for continued treatment with unlabelled GSK2849330. The study is planned to enroll approximately 12-15 subjects.
DOI: 10.25934/00003120
title: Open Label Study to Assess Efficacy and Safety of the Fully Human Anti-TNF-Alpha Monoclonal Antibody Adalimumab

description: The study was to explore the efficacy of adalimumab in subjects previously treated with infliximab and failed infliximab treatment due to lack of efficacy or intolerance. To explore the safety of adalimumab in subjects previously treated with infliximab.
DOI: 10.25934/00003811
title: Subject Understanding of the Risks Associated With ZYBAN®, WELLBUTRIN®, WELLBUTRIN SR®, and WELLBUTRIN XL®

description: Branded bupropion hydrochloride products including ZYBAN and WELLBUTRIN range are approved for the treatment of smoking cessation and depressive disorders respectively. The Risk Evaluation and Mitigation Strategy (REMS) for ZYBAN was initially approved in 2010 and consists of a Medication Guide and a timetable for REMS assessments submission at 18 months, 3 years and 7 years from the date of initial approval of REMS. The present study is a 7-year REMS assessment to evaluate subjects' understanding of the potential serious risk of neuropsychiatric adverse events associated with the use of ZYBAN, WELLBUTRIN, WELLBUTRIN SR, and WELLBUTRIN XL. The assessment will be a 20-minutes Knowledge, Attitudes and Behavior (KAB) survey and will be conducted among approximately 125 subjects currently using or who have filled a prescription for a branded bupropion product for smoking cessation within the 6 months prior to survey administration. ZYBAN, WELLBUTRIN, WELLBUTRIN SR, and WELLBUTRIN XL are registered trade marks of the GSK group of companies.
DOI: 10.25934/00006693
title: An Open-label Study to Evaluate Correct Use and Ease of Use of the ELLIPTA Dry Powder Inhaler (DPI) in Pediatric Patients Currently Receiving Inhaled Therapy for Treatment of Their Asthma

description: Asthma is a chronic inflammatory disease of airways and lungs that results in hyper-reactivity and clinically relevant episodes of wheezing. This study has been designed to assess the correct use and ease of use of the ELLIPTA® DPI in pediatric subjects with asthma. ELLIPTA DPI is easy to use, requires few steps, is consistent in dosing and eliminates the hand-breath co-ordination required for metered dose inhalers (MDIs). Subjects will be stratified by age into two strata: Stratum 1: subjects in the age group of 5 to 7 years and Stratum 2: Subjects in the age group of 8 to 11 years. All subjects will be trained by Health care professionals (HCP) for the correct use of ELLIPTA DPI. Subjects will be given three chances to attempt correct use of ELLIPTA DPI; subsequently, if the subject is not successful, the parent/guardian will be able to help instruct the subject on the correct use of the ELLIPTA DPI, for two more attempts. The subjects who will be enrolled in the study will take placebo ELLIPTA DPI once daily. After 28 days subjects will be randomized in 1:1 to receive a questionnaire (Version A and B). After completion of the questionnaire on ELLIPTA DPI ease of use, subject's ability to use ELLIPTA DPI correctly will be re-assessed. Approximately 219 subjects will be screened to participate in the study. The study will be conducted for 28 days. ELLIPTA is a registered trademark of GlaxoSmithKline (GSK) group of companies.
DOI: 10.25934/00003121
title: Multicenter Early Access Program of the Safety of Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Active Rheumatoid Arthritis

description: Multicenter Early Access Program of the Safety of Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects with Active Rheumatoid Arthritis
DOI: 10.25934/pr00003576.1
title: Available IPD datapackage for study 'A Randomised, Open-label, Phase III Study of BIBW 2992 Versus Chemotherapy as First-line Treatment for Patients With Stage IIIB or IV Adenocarcinoma of the Lung Harbouring an EGFR Activating Mutation'

description: This randomised, open label phase III trial will be performed in patients with adenocarcinoma of the lung with tumours harbouring an Epidermal Growth Factor Receptor activating mutation. The objectives of the trial are to compare the efficacy of single agent BIBW 2992, Arm A, with Pemetrexed/Cisplatin chemotherapy, Arm B, as first line treatment for this group of patients.
DOI: 10.25934/pr00004927.1
title: Available IPD datapackage for study 'Randomized, Double-blind, Evaluation in Secondary Stroke Prevention Comparing the EfficaCy and Safety of the Oral Thrombin Inhibitor Dabigatran Etexilate (110 mg or 150 mg, Oral b.i.d.) Versus Acetylsalicylic Acid (100 mg Oral q.d.) in Patients With Embolic Stroke of Undetermined Source (RESPECT ESUS)'

description: This trial will enroll approximately 6,000 patients with recent embolic stroke of unknown source (ESUS). Patients will be randomized to dabigatran or acetylsalicyclic acid (ASA) (1:1 ratio) and have visits every three months. The study doctor may prescribe blinded concomitant ASA for pts with coronary artery disease but this is not mandatory. All Adverse Events (AEs), Serious Adverse Events (SAEs), outcome events will be recorded. The trial will conclude when the required number of stroke events are positively adjudicated which is estimated to take 3 years (including 2.5 years of enrollment).
DOI: 10.25934/pr00005067.0
title: Available IPD datapackage for study 'AXITINIB (AG-013736) AS SECOND LINE THERAPY FOR METASTATIC RENAL CELL CANCER: AXIS TRIAL'

description: The study is designed to demonstrate that axitinib (AG-013736) is superior to sorafenib in delaying tumor progression in patients with metastatic renal cell cancer after failure of one first line regimen.
DOI: 10.25934/pr00006001.0
title: Available IPD datapackage for study 'Randomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Pemetrexed or Docetaxel in Anaplastic Lymphoma Kinase-Positive Advanced Non Small Cell Lung Cancer Patients Previously Treated With Platinum-Based Chemotherapy and Crizotinib'

description: This randomized active-controlled multicenter Phase III open-label study will evaluate and compare between treatment groups the efficacy of alectinib versus chemotherapy in participants with ALK-positive advanced NSCLC who were previously treated with chemotherapy and crizotinib, as measured by investigator-assessed progression-free survival (PFS) and to evaluate and compare between treatment groups the central nervous system (CNS) objective response rate (C-ORR) in participants with measurable CNS metastases at baseline, as assessed by an Independent Review Committee (IRC).
DOI: 10.25934/pr00007116.0
title: Available IPD datapackage for study 'A Randomized Phase 2 Study of AP26113 in Patients With ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib'

description: The purpose of this study is to evaluate the efficacy and safety of two different dosing regimens of brigatinib (AP26113) in participants with ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on therapy with crizotinib.
DOI: 10.25934/pr00003882.0
title: Available IPD datapackage for study 'A Randomized, Multicenter, Open-Label Phase 3 Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab (IMC-11F8) Versus Gemcitabine-Cisplatin Chemotherapy Alone in the First-Line Treatment of Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)'

description: The research study is testing the investigational drug necitumumab (IMC-11F8) in the treatment of advanced non-small cell lung cancer. The aim of this study is to determine if necitumumab, given together with a standard chemotherapy combination consisting of cisplatin and gemcitabine will be more effective in improving participant disease than the standard chemotherapy combination alone.
DOI: 10.25934/pr00004461.1
title: Available IPD datapackage for study 'A Phase 3, Randomized, Double-Blinded Study of IMC-1121B and Best Supportive Care (BSC) Versus Placebo and BSC in the Treatment of Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Following Disease Progression on First-Line Platinum- or Fluoropyrimidine-Containing Combination Therapy'

description: The purpose of this study is to gather information about the use of an investigational drug called Ramucirumab in adenocarcinomas of the stomach or gastroesophageal junction.
DOI: 10.25934/pr00007402.0
title: Available IPD datapackage for study 'A Phase I/III, Randomized, Double-Blind, Placebo-Controlled Study of Carboplatin Plus Etoposide With or Without Atezolizumab (Anti-PD-L1 Antibody) in Patients With Untreated Extensive-Stage Small Cell Lung Cancer'

description: This randomized, Phase I/III, multicenter, double-blinded, placebo-controlled study was designed to evaluate the safety and efficacy of atezolizumab (anti-programmed death-ligand 1 [PD-L1] antibody) in combination with carboplatin plus (+) etoposide compared with treatment with placebo + carboplatin + etoposide in chemotherapy-naive participants with ES-SCLC. Participants will be randomized in a 1:1 ratio to receive either atezolizumab + carboplatin + etoposide or placebo + carboplatin + etoposide on 21-day cycles for four cycles in the induction phase followed by maintenance with atezolizumab or placebo until progressive disease (PD) as assessed by the investigator using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1). Treatment can be continued until persistent radiographic PD or symptomatic deterioration.
DOI: 10.25934/pr00007402.3
title: Available IPD datapackage for study 'A Phase I/III, Randomized, Double-Blind, Placebo-Controlled Study of Carboplatin Plus Etoposide With or Without Atezolizumab (Anti-PD-L1 Antibody) in Patients With Untreated Extensive-Stage Small Cell Lung Cancer'

description: This randomized, Phase I/III, multicenter, double-blinded, placebo-controlled study was designed to evaluate the safety and efficacy of atezolizumab (anti-programmed death-ligand 1 [PD-L1] antibody) in combination with carboplatin plus (+) etoposide compared with treatment with placebo + carboplatin + etoposide in chemotherapy-naive participants with ES-SCLC. Participants will be randomized in a 1:1 ratio to receive either atezolizumab + carboplatin + etoposide or placebo + carboplatin + etoposide on 21-day cycles for four cycles in the induction phase followed by maintenance with atezolizumab or placebo until progressive disease (PD) as assessed by the investigator using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1). Treatment can be continued until persistent radiographic PD or symptomatic deterioration.
DOI: 10.25934/pr00005997.3
title: Available IPD datapackage for study 'A Phase III, Open-Label, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Bevacizumab Versus Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma'

description: This multi-center, randomized, open-label study will evaluate the efficacy and safety of atezolizumab plus bevacizumab versus sunitinib in participants with inoperable, locally advanced, or metastatic RCC who have not received prior systemic active or experimental therapy, either in the adjuvant or metastatic setting.
DOI: 10.25934/pr00007528.0
title: Available IPD datapackage for study 'Dextromethorphan in Fibromyalgia'

description: The objective of this protocol is to evaluate if Dextromethorphan (DXM) reduces Fibromyalgia (FM) pain. DXM is a drug found in several over-the-counter products, including cough suppressants. The drug may reduce FM pain by suppressing inflammation in the central nervous system. The investigators will be observing the effects of DXM on daily self-reported pain measures in people with FM. If DXM reduces FM pain, it will provide important information about the nature of FM pathophysiology.
DOI: 10.25934/pr00007792
title: A PHASE 2, OPEN-LABEL, SINGLE-ARM STUDY OF 18F-SODIUM FLUORIDE PET/CT BONE IMAGING IN ENZALUTAMIDE-TREATED CHEMOTHERAPY-NAÏVE PATIENTS WITH BONE-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

description: The purpose of this study is to evaluate 18F-sodium fluoride positron-emission tomography / computed tomography (18F-NaF PET/CT) imaging as a method for determining treatment response in metastatic bone lesions in patients who are receiving enzalutamide for castration-resistant prostate cancer.
DOI: 10.25934/pr00007865
title: A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Group, Study Followed by a Dose-Blind Period and Open-Label Follow-Up to Evaluate the Efficacy and Safety of Certolizumab Pegol in Subjects With Moderate to Severe Chronic Plaque Psoriasis

description: The purpose of this study is to investigate the efficacy and safety of two dose levels of certolizumab pegol in adults with moderate to severe chronic plaque psoriasis.
DOI: 10.25934/pr00008149
title: Bioequivalence Study of the Fixed Dose Combination of 5 mg Saxagliptin/1000 mg Metformin XR (Manufactured in Mt Vernon, IN) Relative to 5 mg of Onglyza and 2 × 500 mg Glucophage XR Coadministered to Healthy Subjects in the Fed State and Steady State Pharmacokinetic Assessment of the Fixed Dose Combination of 5 mg Saxagliptin/1000 mg Metformin XR

description: The purpose of this study is to demonstrate bioequivalence (BE) of a 5 mg saxagliptin/1000 mg metformin extended release (XR) fixed-dose combination (FDC) tablet (manufactured in Mt Vernon, Indiana) relative to a coadministered 5 mg Onglyza tablet (saxagliptin, manufactured in Mt Vernon, Indiana) and two 500 mg Glucophage XR tablets (metformin XR, manufactured in Evansville, Indiana) in the fed state in healthy subjects.
DOI: 10.25934/pr00001505.0
title: Available IPD datapackage for study 'A Randomized Controlled Study of YONDELIS (Trabectedin) or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma'

description: The purpose of this study is to evaluate whether overall survival for the trabectedin group is superior to the dacarbazine group for patients with advanced L-sarcoma (liposarcoma or leiomyosarcoma).
DOI: 10.25934/pr00007372.4
title: Available IPD datapackage for study 'A Phase III, Open-Label, Randomized Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma'

description: This study will evaluate the efficacy and safety of atezolizumab in combination with bevacizumab compared with sorafenib in participants with locally advanced or metastatic Hepatocellular Carcinoma (HCC) who have received no prior systemic treatment.
DOI: 10.15468/dl.mwz99p
title: Occurrence Download

description: A dataset containing 14239 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is one of (Dysphania pumilio (R.Br.) Mosyakin & Clemants, Blitum glandulosum Moq., Chenopodium carinatum f. rubellum Aellen, Chenopodium pumilio R.Br., Blitum pumilio C.A.Mey., Chenopodium pumilio var. oblongifolium J.M.Black, Chenopodium glandulosum (Moq.) F.Muell., Chenopodium pumilio f. glandulosum (Moq.) Aellen, Chenopodium pumilio f. rubellum (Aellen) Aellen, Blitum pumilio (R.Br.) C.A.Mey. ex Steud., Ambrina pumilio (R.Br.) Moq., Neobotrydium pumilio (R.Br.) M.L.Zhang & G.L.Chu, Teloxys pumilio (R.Br.) W.A.Weber)",
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "Year is greater than or equal to 2000"
 ]
}

 The dataset includes 14239 records from 209 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0012520-241126133413365/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.krzwze
title: Occurrence Download

description: A dataset containing 1 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Continent is Africa",
 "Country is South Africa",
 "OccurrenceStatus is Present",
 "TaxonKey is Ipomoea tricolor Cav."
 ]
}

 The dataset includes 1 records from 1 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0012521-241126133413365/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.17632/3w9662wjpr.1
title: Data for: A principled approach to synthesize neuroimaging data for replication and exploration

description: The synthetic predictor tables and fully synthetic neuroimaging data produced for the analysis of fully synthetic data in the current study are available as Research Data available from Mendeley Data. Ten fully synthetic datasets include synthetic gray matter images (nifti files) that were generated for analysis with simulated participant data (text files). An archive file predictor_tables.tar.gz contains ten fully synthetic predictor tables with information for 264 simulated subjects. Due to large file sizes, a separate archive was created for each set of synthetic gray matter image data: RBS001.tar.gz, …, RBS010.tar.gz. Regression analyses were performed for each synthetic dataset, then average statistic maps were made for each contrast, which were then smoothed (see accompanying paper for additional information).

The supplementary materials also include commented MATLAB and R code to implement the current neuroimaging data synthesis methods (SKexample.zip). The example data were selected from an earlier fMRI study (Kuchinsky et al., 2012) to demonstrate that the current approach can be used with other types of neuroimaging data. The example code can also be adapted to produce fully synthetic group-level datasets based on observed neuroimaging data from other sources. The zip archive includes a document with important information for performing the example analyses, and details that should be communicated with recipients of a synthetic neuroimaging dataset.

Kuchinsky, S.E., Vaden, K.I., Keren, N.I., Harris, K.C., Ahlstrom, J.B., Dubno, J.R., Eckert, M.A., 2012. Word intelligibility and age predict visual cortex activity during word listening. Cerebral Cortex 22, 1360–71. https://doi.org/10.1093/cercor/bhr211
DOI: 10.15468/dl.g4sdkn
title: Occurrence Download

description: A dataset containing 16 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is one of (Begonia hainanensis Chun & F.Chun)"
 ]
}

 The dataset includes 16 records from 7 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0012523-241126133413365/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.5mzaqu
title: Occurrence Download

description: A dataset containing 0 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Paradeontacylix megalaspium Lakshmi & Madhavi, 2007",
 "Geometry POLYGON((170 20, 170 50, 120 50, 120 20, 170 20))",
 "HasCoordinate is true"
 ]
}

 The dataset includes 0 records from 0 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0012522-241126133413365/datasets/export for details.
DOI: 10.15468/dl.8sz6zg
title: Occurrence Download

description: A dataset containing 5282 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is Murdannia nudiflora (L.) Brenan"
 ]
}

 The dataset includes 5282 records from 279 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0012525-241126133413365/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.25549/independent-c69-4459
title: Philadelphia and its police, 1987-03

description: Reports - Philadelphia Police Study Task Force. Philadelphia and its police: Toward a new partnership, 1987 March. PART OF A SERIES: The series consists of miscellaneous source materials that were collected and analyzed over the course of the Independent Commission's investigation. Included are the following: article clippings pertaining to the Rodney King incident; legal materials related to the Gates v. Board of Los Angeles Police Commissioners case, including appellate documents, court transcripts, preliminary injunctions, and briefs; black-and-white photographs; essays and articles related to police misconduct; issues of The Thin Blue Line, the Los Angeles Police Protective League's monthly publication, and Perspectives on Policing, a newsletter published by the United States Department of Justice; materials regarding policing issues in other major United States cities, including commission reports and Pate and Hamilton's book The Big Six: Policing America's Largest Cities; supplemental materials and appendices to the Independent Commission's report; requests for copies of the Commission report; transcripts from public hearings conducted by members of the Commission; and instructional materials related to the Video Incident Capture System, a video camera system that provides video and audio records of police officers' activities while on patrol.
DOI: 10.25549/independent-c69-4456
title: Philadelphia and its police, 1987-03

description: Reports - Philadelphia Police Study Task Force. Philadelphia and its police: Toward a new partnership, 1987 March. PART OF A SERIES: The series consists of miscellaneous source materials that were collected and analyzed over the course of the Independent Commission's investigation. Included are the following: article clippings pertaining to the Rodney King incident; legal materials related to the Gates v. Board of Los Angeles Police Commissioners case, including appellate documents, court transcripts, preliminary injunctions, and briefs; black-and-white photographs; essays and articles related to police misconduct; issues of The Thin Blue Line, the Los Angeles Police Protective League's monthly publication, and Perspectives on Policing, a newsletter published by the United States Department of Justice; materials regarding policing issues in other major United States cities, including commission reports and Pate and Hamilton's book The Big Six: Policing America's Largest Cities; supplemental materials and appendices to the Independent Commission's report; requests for copies of the Commission report; transcripts from public hearings conducted by members of the Commission; and instructional materials related to the Video Incident Capture System, a video camera system that provides video and audio records of police officers' activities while on patrol.